Hay J W, Ernst R L
Am J Public Health. 1987 Sep;77(9):1169-75. doi: 10.2105/ajph.77.9.1169.
This paper estimates the economic costs of Alzheimer's Disease to individuals and to society, based on review of published Alzheimer's Disease-related research. The analysis is derived from epidemiological projections and cost information for the United States population in 1983. Estimated costs include both direct medical care and social support costs, as well as indirect costs, such as support services provided by family or volunteers, and the value of lost economic productivity in Alzheimer's Disease patients. Mid-range estimates of net annual expected costs for an Alzheimer's Disease patient, excluding the value of lost productivity, are $18,517 in the first year and $17,643 in subsequent years, with direct medical and social services comprising about half of these costs. Under base case assumptions, the total cost of disease per patient in 1983, was $48,544 to $493,277, depending upon patient's age at disease onset. The estimated present value of total net costs to society for all persons first diagnosed with Alzheimer's Disease in 1983 was $27.9-31.2 billion. Development of a public or private insurance market for the economic burdens of Alzheimer's Disease would fill some of the gaps in the current US system of financing long-term chronic disease care.
本文基于对已发表的与阿尔茨海默病相关研究的综述,估算了阿尔茨海默病给个人和社会带来的经济成本。该分析源自1983年美国人口的流行病学预测和成本信息。估算成本包括直接医疗护理和社会支持成本,以及间接成本,如家庭或志愿者提供的支持服务,以及阿尔茨海默病患者经济生产力损失的价值。阿尔茨海默病患者每年净预期成本的中等估算值(不包括生产力损失的价值),第一年为18,517美元,随后几年为17,643美元,其中直接医疗和社会服务约占这些成本的一半。在基本假设情况下,1983年每位患者的疾病总成本为48,544美元至493,277美元,具体取决于疾病发病时患者的年龄。1983年首次被诊断为阿尔茨海默病的所有人给社会带来的总净成本的估计现值为279亿至312亿美元。为阿尔茨海默病的经济负担建立公共或私人保险市场,将填补美国当前长期慢性病护理融资体系中的一些空白。